Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DPG5T9
|
|||
| Drug Name |
ACT017
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cerebral ischemia [ICD-11: 8B11; ICD-10: I67.8] | Phase 1/2 | [1] | |
| Company |
Acticor Biotech
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Platelet glycoprotein VI (GP6) | Target Info | Inhibitor | [2] |
| KEGG Pathway | ECM-receptor interaction | |||
| Platelet activation | ||||
| Reactome | GPVI-mediated activation cascade | |||
| Cell surface interactions at the vascular wall | ||||
| Platelet Adhesion to exposed collagen | ||||
| WikiPathways | Platelet Adhesion to exposed collagen | |||
| GPVI-mediated activation cascade | ||||
| Cell surface interactions at the vascular wall | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03803007) Acute Ischemic Stroke Interventional Study (ACTIMIS). U.S. National Institutes of Health. | |||
| REF 2 | Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab. Arterioscler Thromb Vasc Biol. 2019 May;39(5):956-964. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.